register

News & Trends - Pharmaceuticals

Abbvie signs up China’s I-Mab for immuno-oncology therapy

Health Industry Hub | September 9, 2020 |

Pharma News: AbbVie and China’s I-Mab biopharma enter a global agreement for the development and commercialisation of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. 

Abbvie stands to pay a lot less for lemzoparlimab than the $4.9bn that Gilead paid to acquire Forty Seven in March 2020.

Topline results of the recent phase 1 clinical trial confirm possible differentiation of lemzoparlimab in drug safety and a more favourable pharmacokinetics profile in cancer patients. Results have shown that lemzoparlimab is well tolerated as a single agent at a dose range of up to 30 mg/kg without any priming dose. In all DLT-evaluable patients, no dose-limiting toxicities or severe hematologic adverse events were observed. 

I-Mab claims that lemzoparlimab is different from the rest because it minimises binding to red blood cells. The company said this is what caused adverse events like anaemia with the older CD47-antibodies.

Abbvie will pay $200M up front to license lemzoparlimab outside China. A further $840M will be due if the project hits certain clinical and regulatory milestones, and another $900M in milestones is dependent on sales.

At just under $2bn in biodollars, this is the biggest outlicensing deal by a China-based biotech company.

There is also the potential to combine lemzoparlimab with other Abbvie agents. The I-Mab execs highlighted Venclexta and lemzoparlimab as one potential combo.

As for the competition, Gilead will initiate phase III trial of magrolimab, putting it ahead of a sizeable pack that includes Trillium, another potential acquisition target. With pharma interest in CD47 resurgent more M&As could be coming.


News & Trends - Biotechnology

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

Health Industry Hub | April 23, 2024 |

Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]

More


News & Trends - MedTech & Diagnostics

Federal government invests in Siemens Healthineers scanner to 'reduce wait times' for cancer diagnosis

Federal government invests in Siemens Healthineers scanner to ‘reduce wait times’ for cancer diagnosis

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: The Albanese Government is investing $12 million through the 2024–25 Budget, to purchase and install a […]

More


News & Trends - MedTech & Diagnostics

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: Starting from July 2024, Cardiac Implantable Electronic Devices (CIED) listed on the Prescribed List (PL) will […]

More


News & Trends - Biotechnology

CSL's world-first gene therapy heads for MSAC assessment

CSL’s world-first gene therapy heads for MSAC evaluation

Health Industry Hub | April 23, 2024 |

Biotech News: CSL’s world-first gene therapy for haemophilia B is scheduled for consideration at the upcoming Medical Services Advisory Committee (MSAC) […]

More


This content is copyright protected. Please subscribe to gain access.